Failure in late stages of the drug development pipeline is one of the major challenges that the pharmaceutical industry faces today. Human organ-on-a-chip (Organ-Chip) technology has the potential to disrupt preclinical drug discovery, as it has been shown to recapitulate organ-level pathophysiology and clinical responses. Additionally, industrial guidelines have been published that describe the criteria for qualifying preclinical models for a particular use application; however, systematic and quantitative evaluation of Organ-Chips’ predictive value has not been conducted to date.
To explore how this challenge might be approached, 780 human Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury caused by small molecules. Across a blinded set of 27 known hepatotoxic and non-toxic drugs, the Liver-Chip demonstrated a sensitivity of 87% and a specificity of 100%.
Watch this webinar to discover:
- Why preclinical models with greater predictive validity will improve clinical success and productivity
- How the Emulate Liver-Chip performed against the IQ MPS guidelines and compared to animal models as well as hepatic spheroids
- What the economic impact of the Liver-Chip in routine use of small-molecule liver toxicity could be
- Where the Emulate Liver-Chip can be implemented into the drug development process